FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210328896> ?p ?o ?g. }

• W4210328896 endingPage "578" @default.
• W4210328896 startingPage "565" @default.
• W4210328896 abstract "Modified nucleosides show therapeutic promise for antiviral therapies. However, issues including the emergence of drug resistance, toxicity, and coinfections have posed new challenges for nucleoside-based antiviral drug discovery, particularly in the era of the coronavirus disease 2019 (COVID-19) pandemic. Chemical manipulation could impact the antiviral potency, safety, and drug resistance of nucleosides. Generally, modified nucleosides are difficult to recognize by intracellular important enzymes as substrates and thus exhibit low toxicity. 4'-Modified nucleosides represent an important subclass of modified nucleosides for antiviral therapies. To prevent the occurrence of drug resistance, 4'-modified nucleosides should have 3'-OH, which should also be chemically unreactive for proviral DNA biosynthesis. The absence of 3'-OH may explain the occurrence of drug resistance for censavudine. The introduction of 4'-substituents improves enzymatic and acidic stability and makes the nucleosides more lipophilic, thus improving cell permeability and bioavailability. Steric hindrance between the 4'-substituent and 3'-OH changes the furanose conformation to the 3'-endo type, in which the oxygen lone pair on the furanose ring could not form an oxocarbonium ion for glycolysis. Currently, seven 4'-modified nucleoside drug candidates such as azvudine (also known as FNC), islatravir, censavudine, balapiravir, lumicitabine, AL-335, and 4-azidothymidine have progressed into clinical stages for treating viral infections. Of note, FNC was officially approved by NMPA in July 2021 for use in adult patients with high HIV-1 virus loads (nos. H20210035 and H20210036), providing an alternative therapeutic for patients with HIV-1. The long-term cellular retention of FNC suggests its potential as a long-lasting pre-exposure prophylaxis (PrEP) agent for preventing HIV-1 infection. Mechanistically, FNC not only inhibited HIV-1 reverse transcription and replication but also restored A3G expression in peripheral blood CD4+ T cells in HIV-1 patients receiving FNC. The 4'-azido group in azvudine stabilizes the 3'-C-endo (north) conformation by steric effects and the formation of an intramolecular hydrogen bond with the 3'-OH group, thus decreasing the nucleophilicity of 3'-OH. The north conformation may also enhance the phosphorylation efficiency of FNC by cellular kinases. Encouragingly, FNC, islatravir, and balapiravir show promise for the treatment of coronaviruses, of which FNC has advanced to phase 3 clinical trials in different countries to treat patients with COVID-19 (clinical trial numbers: NCT04668235 and NCT04425772). FNC cured the COVID-19 disease in almost all patients and showed better therapeutic efficacy than remdesivir. In this Account, we provide an overview of 4'-modified nucleoside analogs in clinical stages for antiviral therapies, highlighting the drug discovery strategies, structure-activity relationship studies, and preclinical/clinical studies and also give our perspectives on nucleoside-based antiviral drug discovery." @default.
• W4210328896 created "2022-02-08" @default.
• W4210328896 creator A5020603394 @default.
• W4210328896 date "2022-01-25" @default.
• W4210328896 modified "2023-10-18" @default.
• W4210328896 title "4′-Modified Nucleosides for Antiviral Drug Discovery: Achievements and Perspectives" @default.
• W4210328896 cites W1523134308 @default.
• W4210328896 cites W1552317649 @default.
• W4210328896 cites W1823429634 @default.
• W4210328896 cites W1966804793 @default.
• W4210328896 cites W1979033897 @default.
• W4210328896 cites W1985352714 @default.
• W4210328896 cites W1986058047 @default.
• W4210328896 cites W1988798592 @default.
• W4210328896 cites W1997448570 @default.
• W4210328896 cites W2008093637 @default.
• W4210328896 cites W2014886160 @default.
• W4210328896 cites W2016590117 @default.
• W4210328896 cites W2017624799 @default.
• W4210328896 cites W2019866996 @default.
• W4210328896 cites W2030870635 @default.
• W4210328896 cites W2032364687 @default.
• W4210328896 cites W2032719974 @default.
• W4210328896 cites W2033978085 @default.
• W4210328896 cites W2034741032 @default.
• W4210328896 cites W2036535362 @default.
• W4210328896 cites W2040472577 @default.
• W4210328896 cites W2059679474 @default.
• W4210328896 cites W2072290017 @default.
• W4210328896 cites W2072291558 @default.
• W4210328896 cites W2072489534 @default.
• W4210328896 cites W2079055165 @default.
• W4210328896 cites W2079290025 @default.
• W4210328896 cites W2083470546 @default.
• W4210328896 cites W2091220577 @default.
• W4210328896 cites W2103800735 @default.
• W4210328896 cites W2106196384 @default.
• W4210328896 cites W2113988928 @default.
• W4210328896 cites W2127043999 @default.
• W4210328896 cites W2134793945 @default.
• W4210328896 cites W2135996840 @default.
• W4210328896 cites W2142565170 @default.
• W4210328896 cites W2146156364 @default.
• W4210328896 cites W2175569396 @default.
• W4210328896 cites W2220206733 @default.
• W4210328896 cites W2316438868 @default.
• W4210328896 cites W2328878243 @default.
• W4210328896 cites W2334783812 @default.
• W4210328896 cites W2341929619 @default.
• W4210328896 cites W2462336466 @default.
• W4210328896 cites W2467247336 @default.
• W4210328896 cites W2486192779 @default.
• W4210328896 cites W2552693719 @default.
• W4210328896 cites W2605406690 @default.
• W4210328896 cites W2767817851 @default.
• W4210328896 cites W2789343266 @default.
• W4210328896 cites W2796947392 @default.
• W4210328896 cites W2801450366 @default.
• W4210328896 cites W2889080666 @default.
• W4210328896 cites W2893116113 @default.
• W4210328896 cites W2897934086 @default.
• W4210328896 cites W2900396794 @default.
• W4210328896 cites W2905424382 @default.
• W4210328896 cites W2934210165 @default.
• W4210328896 cites W2951642511 @default.
• W4210328896 cites W2952022753 @default.
• W4210328896 cites W2982392507 @default.
• W4210328896 cites W3005573859 @default.
• W4210328896 cites W3008919653 @default.
• W4210328896 cites W3012335389 @default.
• W4210328896 cites W3013003151 @default.
• W4210328896 cites W3015484735 @default.
• W4210328896 cites W3022622509 @default.
• W4210328896 cites W3024414727 @default.
• W4210328896 cites W3042672622 @default.
• W4210328896 cites W3043552482 @default.
• W4210328896 cites W3043765868 @default.
• W4210328896 cites W3045003495 @default.
• W4210328896 cites W3091853899 @default.
• W4210328896 cites W3128880495 @default.
• W4210328896 cites W3130483557 @default.
• W4210328896 cites W313245505 @default.
• W4210328896 cites W3133124380 @default.
• W4210328896 cites W3137876609 @default.
• W4210328896 cites W4200084675 @default.
• W4210328896 cites W751303237 @default.
• W4210328896 cites W766222058 @default.
• W4210328896 doi "https://doi.org/10.1021/acs.accounts.1c00697" @default.
• W4210328896 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35077644" @default.
• W4210328896 hasPublicationYear "2022" @default.
• W4210328896 type Work @default.
• W4210328896 citedByCount "25" @default.
• W4210328896 countsByYear W42103288962022 @default.
• W4210328896 countsByYear W42103288962023 @default.
• W4210328896 crossrefType "journal-article" @default.
• W4210328896 hasAuthorship W4210328896A5020603394 @default.
• W4210328896 hasConcept C114851261 @default.
• W4210328896 hasConcept C185592680 @default.

• next